# Frequent Cannabis Use Linked With Higher Seizure Burden in Drug-Resistant Epilepsy

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/ced-frequent-cannabis-use-linked-with-h-2026-09-29/
> **Published:** 2026-09-30T09:08:36-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:32:52-04:00
> **Clinical Summary:** medical cannabis research: Physician review of Frequent cannabis use and the association with seizure burden in drug-resistant epilepsy.: evidence analysis,...

---

CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Frequent cannabis use and the association with seizure burden in drug-resistant epilepsy..

Clinical Insight | CED Clinic
This retrospective epilepsy monitoring unit study raises a practical clinical warning: frequent cannabis use, defined as at least 20 days per month, clustered with markers of more severe drug-resistant epilepsy. Among 64 adults, frequent users had a higher prevalence of focal to bilateral tonic-clonic seizures, higher annualized seizure frequency, and used more antiseizure medications. The findings do not establish whether cannabis worsened seizures, whether patients with more severe epilepsy used cannabis more often, or whether unmeasured factors such as product THC potency, sleep, adherence, stress, or comorbid substance use drove the association. Clinically, the paper supports careful cannabis history-taking in epilepsy care.

Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight

AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts.
Primary TopicClinical study review: Frequent Cannabis Use Linked With Higher Seizure B.
Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42803888/)

A small EMU cohort found frequent cannabis users with drug-resistant epilepsy had more focal to bilateral tonic-clonic seizures and greater medication burden, but the study cannot prove cannabis caused worse epilepsy.

What This Study Teaches Us
In 64 adults with drug-resistant epilepsy admitted to an EMU, 22 frequent cannabis users had higher FBTCS prevalence than 42 nonusers, 90.9% versus 57.1%, with an approximate risk ratio of 1.59, higher annualized FBTCS frequency, 3.00 versus 1.32, and greater ASM burden, 3.05 versus 2.21 medications. Imaging analyses did not show significant mesial temporal lobe volumetric differences.

Why This Matters
For patient care, the study highlights frequent cannabis use as a clinical flag in drug-resistant epilepsy, especially when tonic-clonic seizure burden and medication complexity are high. It supports more precise cannabis exposure documentation, seizure safety counseling, and avoidance of simplistic reassurance about frequent high-THC use.

Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceEpilepsiaPublication Date2026Sep28Evidence LevelJournal ArticleFocus AreaFrequent Cannabis Use Linked With Higher Seizure Burden in DLead AuthorsSantiago Philibert-Rosas, Kaitlin A Guston, Mariel Kalkach-Aparicio, Abigail Keller et al.DOI10.1002/epi.70456PMIDPMID: 42803888

Clinical Bottom Line
This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations.

Headline vs. Reality Truth Meter | Clinical Analysis

**Mainstream Media Claim:** Frequent cannabis use makes drug-resistant epilepsy worse and increases dangerous seizures.

**Primary Journal Data:** In 64 adults admitted to a tertiary EMU, 22 frequent cannabis users had higher FBTCS prevalence than 42 nonusers, 90.9% versus 57.1%, greater annualized FBTCS frequency, 3.00 versus 1.32, higher ASM burden, 3.05 versus 2.21 medications, and shorter time from epilepsy onset to EMU admission, 5.0 versus 18.1 years.

**Dr. Caplan’s Clinical Verdict:** The signal is clinically important but not causal. Frequent cannabis use should trigger a more detailed seizure, product, THC, CBD, adherence, sleep, and safety review, not an automatic assumption that cannabis is the cause.

Primary Analysis | Frequent cannabis use and the associatio

**Study Overview:** Cannabis use has increased substantially, with modern products characterized by high tetrahydrocannabinol concentrations and variable composition. The relationship between frequent cannabis use and epilepsy outcomes remains uncertain. We examined the association between frequent cannabis use and epilepsy severity, clinical phenotype, and imaging characteristics in patients admitted to an epilepsy monitoring unit (EMU). This retrospective cohort study included adults with drug-resistant epilepsy admitted to a tertiary care EMU. Patients were classified based on cannabis use documented in the electronic medical record over the year prior to admission. Frequent use was defined as cannabis use on ≥20 days/month; patients with low use were excluded. Primary outcomes included markers of epilepsy severity, including time from epilepsy onset to EMU admission, presence and frequency of focal to bilateral tonic-clonic seizures (FBTCS), and antiseizure medication (ASM) burden. Secondary analyses evaluated epilepsy syndrome and mesial temporal lobe volumetric measures. Sixty-four patients were included (42 nonusers and 22 frequent users). Frequent cannabis use was associated with shorter time from epilepsy onset to EMU admission (mean [SD] = 5.0 [4.2] vs. 18.1 [16.3] years, p = .004), higher prevalence of FBTCS (90.9% vs. 57.1%, p = .04), greater annualized FBTCS frequency (mean [SD] = 3.00 [3.63] vs. 1.32 [3.87], p = .003), and higher ASM burden (mean [SD] = 3.05 [1.00] vs. 2.21 [1.14], p = .027). All frequent cannabis users had temporal lobe epilepsy (TLE), although the between-group difference in TLE prevalence was not statistically significant. No significant group differences were observed in imaging analysis. In this cohort of patients with drug-resistant epilepsy, frequent cannabis use was associated with markers of increased epilepsy severity, including higher FBTCS burden, shorter time to specialized EMU evaluation, and greater ASM requirements. Prospective studies using objective cannabis exposure measures are needed to clarify the relationship between cannabis use and epilepsy outcomes.

**Primary Source & Scope:** Published in *Epilepsia* (2026Sep28) conducted by Santiago Philibert-Rosas, Kaitlin A Guston, Mariel Kalkach-Aparicio, Abigail Keller et al.. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42803888/) | **Primary Record:** DOI: 10.1002/epi.70456 | PMID: 42803888

How Strong Is This Evidence?
The study uses a clinically relevant EMU population and reports concrete endpoints, including FBTCS prevalence, annualized FBTCS frequency, time from epilepsy onset to EMU admission, antiseizure medication burden, epilepsy syndrome, and imaging measures. Statistical comparisons showed significant differences for several severity markers, but the total sample was only 64 patients with 22 frequent users, limiting multivariable control and subgroup inference.

Where This Paper Deserves Skepticism
The central limitation is confounding by severity: patients with more severe or distressing epilepsy may be more likely to use cannabis frequently. Cannabis exposure was extracted from electronic medical record documentation rather than verified by product testing, toxicology, dose logs, or cannabinoid levels. Important confounders such as adherence, sleep, psychiatric symptoms, THC potency, CBD dose, alcohol use, and withdrawal patterns may not have been adequately captured.

What This Paper Does Not Show
This study does not prove that cannabis causes worsening epilepsy, nor does it prove that stopping cannabis will reduce seizure frequency. It also does not evaluate prescription cannabidiol efficacy, establish a safe THC threshold, or justify broad regulatory conclusions about all [cannabis products](https://cedclinic.com/cbd-gummies-daily-use-evidence-men/) in epilepsy.

How This Fits With the Broader Clinical Conversation

Clinical research into Frequent cannabis use and the association with sei is progressing through rigorously documented peer-reviewed cohorts.

Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries.

Editorial Commentary

*The most important feature of this paper is the specific seizure signal, not the cannabis label alone. Focal to bilateral tonic-clonic seizures are among the outcomes clinicians most want to prevent, and the frequent-use group showed both higher prevalence and higher annualized frequency. That makes the association clinically relevant even though the study cannot decide whether cannabis was a driver, marker, or attempted self-treatment response to more severe disease.*

*The paper also exposes a recurring weakness in cannabis research: exposure is too often documented as use or nonuse when the pharmacology depends on dose, THC potency, CBD content, route, regularity, and product reliability. A patient using nightly high-THC concentrates is not pharmacologically equivalent to a patient using a consistent CBD-dominant preparation, yet both may be captured under broad cannabis categories in routine records.*

What a Careful Reader Should Take Away
Frequent cannabis use in drug-resistant epilepsy should be treated as a clinical signal requiring careful assessment, not as automatic proof of harm. Patients should review cannabis patterns with an epilepsy clinician before changing use, especially if tonic-clonic seizures are present.

Evidence Interpretation Guide

Table of Contents

- [How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading)
- [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis)
- [Patient Communication](#Patient_Communication)
- [Dosing & Formulations](#Dosing_Formulations)
- [Safety & Side Effect Profile](#Safety_Side_Effect_Profile)
- [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics)
- [Mechanisms & Physiology](#Mechanisms_Physiology)
- [Research Limitations](#Research_Limitations)
- [Future Outlook](#Future_Outlook)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

## How to Interpret This Clinical Study

Navigating biomedical publications regarding Frequent cannabis use and the association wit requires reviewing study methodology and patient eligibility.

### Three Rules for Critical Reading

**Critical Rule**Separate association from causation because the study is retrospective and cannot determine whether cannabis worsened epilepsy or more severe epilepsy led to more cannabis use.

**Critical Rule**Interrogate the exposure definition because use on at least 20 days per month does not specify THC dose, CBD dose, formulation, route, potency, or consistency.

**Critical Rule**Focus on clinically meaningful endpoints because focal to bilateral tonic-clonic seizures, antiseizure medication burden, and EMU referral timing matter more than a generic cannabis user label.

Key Evaluation Question
Were frequent cannabis users already different in epilepsy severity, comorbid symptoms, adherence, sleep, or product exposure before the measured outcomes?

The Patient Question
Given my seizure type, medication plan, and cannabis product details, should I change anything, and how can we do that safely?

The Bottom Line
In a small EMU cohort, frequent cannabis use was associated with greater seizure burden and medication complexity, but better prospective studies are needed before assigning cause.

CED Perspective Lens

## CED Perspective Lens: Eight Clinical Viewpoints

Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives

Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care.

#### Clinical Evidence Synthesis

This retrospective cohort examined 64 adults with drug-resistant epilepsy admitted to a tertiary epilepsy monitoring unit. Patients were classified as nonusers or frequent cannabis users, with frequent use defined as at least 20 days per month in the prior year. Low-frequency users were excluded, sharpening contrast but reducing generalizability.

Frequent users had more markers of severity: FBTCS prevalence was 90.9% versus 57.1%, annualized FBTCS frequency was 3.00 versus 1.32, and antiseizure medication burden was 3.05 versus 2.21 medications. These are associations within a selected EMU population, not proof of causation.

Lens takeawayThe study identifies a severity signal, not a definitive cannabis-induced seizure mechanism.

#### Patient Communication

For patients, the most useful message is neither reassurance nor alarm. Frequent cannabis use in this cohort traveled with more severe epilepsy features, especially focal to bilateral tonic-clonic seizures. That deserves discussion because these seizures carry higher injury risk, driving restrictions, and sudden unexpected death in epilepsy considerations.

Clinicians should ask nonjudgmentally about frequency, product type, THC percentage, CBD content, route, timing, missed medications, sleep disruption, and withdrawal patterns. A patient who uses cannabis daily should not abruptly stop without a seizure safety plan and medical supervision.

Lens takeawayDaily cannabis use in epilepsy should prompt structured review, not stigma or silence.

#### Dosing & Formulations

The study did not measure dose, cannabinoid ratios, terpene profile, route, dispensary source, or objective blood levels. That matters because frequent cannabis use may include high-THC inhaled products, balanced THC:CBD products, CBD-dominant preparations, or variable unregulated products with different neurologic effects.

Evidence for prescription cannabidiol in specific epilepsy syndromes should not be conflated with frequent use of modern high-THC cannabis. For clinical care, the missing dosing data are central, because seizure outcomes may differ by THC exposure, CBD dose, consistency, and medication interactions.

Lens takeawayFrequency alone is an incomplete exposure measure for epilepsy cannabis counseling.

#### Safety & Side Effect Profile

The safety concern is not simply cannabis use, but cannabis use in a population already experiencing drug-resistant epilepsy. Higher focal to bilateral tonic-clonic seizure burden is clinically meaningful because these seizures are linked with injuries, emergency care, driving restrictions, and increased sudden unexpected death in epilepsy risk.

Cannabis may also affect cognition, anxiety, sleep architecture, medication adherence, and intoxication risk. In some patients, withdrawal, heavy THC exposure, or irregular use could plausibly destabilize seizure thresholds, but this paper cannot isolate those pathways.

Lens takeawaySeizure safety planning should include cannabis patterns, withdrawal risk, and medication adherence.

#### Regulatory & Policy Dynamics

This paper sits at the intersection of [medical cannabis](https://cedclinic.com/cbd-gummies-for-sexual-enhancement-evidence/) access and epilepsy safety. Public policy often treats cannabis as a single exposure, while clinical epilepsy care requires distinctions among prescription cannabidiol, regulated dispensary products, high-THC flower, concentrates, edibles, and untested products.

Regulators and clinicians should not use this study to broadly deny access, because it is small and retrospective. Instead, the findings support better labeling, product testing, cannabinoid documentation, and clinical registries that capture seizure outcomes alongside verified cannabis exposure.

Lens takeawayPolicy should improve exposure transparency rather than reduce epilepsy care to slogans.

#### Mechanisms & Physiology

Mechanistically, the findings are plausible but unresolved. Cannabinoid signaling can influence excitatory and inhibitory neurotransmission, sleep, anxiety, inflammation, and network excitability. CBD has antiseizure evidence in defined syndromes, while THC can produce variable effects depending on dose, tolerance, formulation, and individual vulnerability.

All frequent cannabis users in the cohort had temporal lobe epilepsy, although the between-group difference in temporal lobe epilepsy prevalence was not statistically significant. Imaging did not show significant mesial temporal lobe volume differences, so physiology remains speculative.

Lens takeawayThe biology is credible, but this study does not identify a mechanism.

#### Research Limitations

The study’s major limitation is confounding by indication and severity. Patients with more severe epilepsy may be more likely to use cannabis frequently for seizures, sleep, anxiety, pain, or medication side effects. That could make cannabis appear associated with worse epilepsy even if it is a response to severity.

Exposure was based on documentation in the electronic medical record rather than toxicology, product labels, purchase records, or measured cannabinoid levels. The sample included only 22 frequent users, limiting adjustment, subgroup analysis, and causal inference.

Lens takeawayThe association is clinically notable, but residual confounding remains a central concern.

#### Future Outlook

The next useful studies should be prospective and should measure cannabis exposure objectively. That means capturing THC dose, CBD dose, formulation, route, timing relative to seizures, batch testing, blood or urine cannabinoid measures, antiseizure medication levels, sleep, adherence, and withdrawal episodes.

Clinically, the strongest future endpoint would be change in seizure frequency after standardized cannabis modification, not just comparison between users and nonusers. Randomized trials may be difficult, but prospective registries and pragmatic designs could meaningfully improve guidance.

Lens takeawayBetter exposure measurement is essential before cannabis guidance can become precise.

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.

 
 Health, Longevity, Wellness
 One-on-One Cannabis Guidance
 Metabolic Balance
 

 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](http://CEDclinic.com/book)
 [Cannabis Care](http://CEDclinic.com/book)
 
 

 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

Share this Evidence Watch

[X](https://twitter.com/intent/tweet?text=Frequent+Cannabis+Use+Linked+With+Higher+Seizure+Burden+in+Drug-Resistant+Epilepsy&url=https%3A%2F%2Fcedclinic.com%2Fced-frequent-cannabis-use-linked-with-h-2026-09-29%2F)
[LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-frequent-cannabis-use-linked-with-h-2026-09-29%2F)
[BlueSky](https://bsky.app/intent/compose?text=Frequent+Cannabis+Use+Linked+With+Higher+Seizure+Burden+in+Drug-Resistant+Epilepsy%20https%3A%2F%2Fcedclinic.com%2Fced-frequent-cannabis-use-linked-with-h-2026-09-29%2F)
[Instagram](https://www.instagram.com/drcaplan/)
[Substack](https://doctorapprovedcannabis.substack.com/)
[RSS](https://cedclinic.com/feed/)

Source: [Primary Source: Frequent cannabis use and the association with seizure burden in drug-resistant epilepsy.](https://pubmed.ncbi.nlm.nih.gov/42803888/)

Related Reading at CED ClinicContinue exploring the evidence[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/)

More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia.

[More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/)[Prenatal Cannabis Use and Motivation to Quit: What a New Study Found](https://cedclinic.com/prenatal-cannabis-quit-motivation-study/)

More on this topic: Dr. Caplan evaluates pregnant patients’ motivation to stop or reduce cannabis use, clinical cessation discussions, and quitline uptake barriers.

[More on this topic: Prenatal quit motivation](https://cedclinic.com/prenatal-cannabis-quit-motivation-study/)[Prenatal Cannabis Exposure and Neurodevelopment: What the New Systematic Review Actually Shows](https://cedclinic.com/prenatal-cannabis-neurodevelopment-impact/)

More on this topic: Systematic review analyzing cognitive, behavioral, and developmental trajectories following gestational cannabinoid exposure.

[More on this topic: Fetal neurodevelopment](https://cedclinic.com/prenatal-cannabis-neurodevelopment-impact/)

## Frequently Asked Questions

Does this study prove cannabis causes more seizures in epilepsy?

No. It found an association between frequent cannabis use and higher seizure burden in a small retrospective cohort. It cannot determine whether cannabis worsened seizures or whether people with more severe epilepsy were more likely to use cannabis.

What counted as frequent cannabis use in this study?

Frequent use was defined as cannabis use on at least 20 days per month during the year before epilepsy monitoring unit admission. Patients with lower-frequency use were excluded from the comparison.

How many patients were included?

The study included 64 adults with drug-resistant epilepsy: 42 nonusers and 22 frequent cannabis users. This is a small sample, especially for drawing strong causal conclusions.

What seizure outcome looked worse among frequent cannabis users?

Frequent users had a higher prevalence of focal to bilateral tonic-clonic seizures, 90.9% versus 57.1%, and higher annualized FBTCS frequency, 3.00 versus 1.32. These seizure types are clinically important because they carry greater safety risks.

Did frequent cannabis users take more seizure medications?

Yes. Frequent users had a higher antiseizure medication burden, averaging 3.05 medications compared with 2.21 in nonusers. This may reflect more severe epilepsy, more treatment resistance, or other clinical differences.

Was this about prescription CBD or general cannabis use?

The summary describes cannabis use documented in the medical record, not a controlled prescription CBD trial. The study did not define precise THC dose, CBD dose, formulation, or cannabinoid ratio, which limits interpretation.

Should a patient with epilepsy stop cannabis immediately after reading this?

No abrupt change is advisable without medical guidance. Sudden cessation, sleep disruption, anxiety rebound, or withdrawal could theoretically affect seizure control in some patients. A supervised plan is safer.

What should clinicians ask patients with epilepsy about cannabis?

Clinicians should ask about frequency, route, THC potency, CBD content, timing, product consistency, reasons for use, missed antiseizure medication doses, sleep, alcohol or other substances, and any seizure changes after starting, stopping, or changing products.

Did brain imaging explain the association?

No significant group differences were found in the imaging analysis of mesial temporal lobe volumetric measures. The study therefore does not show that frequent cannabis users had a distinct structural imaging pattern explaining seizure burden.

What is the safest clinical takeaway for patients?

Patients with drug-resistant epilepsy who use cannabis frequently should disclose it to their epilepsy clinician and review seizure logs, medication adherence, product details, and safety precautions. The goal is risk reduction, not blame.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).